288 Fute Zhong Road
Waigaoqiao Free Trade Zone
70 articles with Wuxi Biologics
AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH)
Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines
Antengene Corporation and WuXi Biologics announced that they have signed a strategic cooperation Memorandum of Understanding to co-operate in the development and production of novel drugs, and jointly promote the R&D of innovative oncology therapies.
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
Aravive, Inc., a clinical-stage biopharmaceutical company, and WuXi Biologics, a global company with leading open-access biologics technology platforms, announced a strategic collaboration agreement granting Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
SAN FRANCISCO and SHANGHAI, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2. Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of
Invetx Announces $15 Million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development
Invetx, a pioneering animal health biopharmaceutical company, announced a $15 million Series A financing and founding collaborations with WuXi Biologics and AbCellera.
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, on the positive interim data from the company’s ongoing Phase II TACTI-002 study.
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
Almirall, S.A. (ALM) and WuXi Biologics ("WuXi Bio") (2269.HK) have today announced the signing of an agreement.
This investment follows the 20-year manufacturing Letter of Intent (LOI) signed by WuXi Vaccines earlier this year.
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever
WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi city, China.
The business model of WuXi Vaccines is to build world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines.
Jacobs Wins Contract to Provide Construction Phase Services for WuXi Biologics Biomanufacturing Facility
Plant to be WuXi's first outside of China and largest using single-use bioreactors in Ireland, incorporating leading-edge technology optimized for the flexible production of diverse biologic drugs for customers globally
WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the construction of a new 1.3 million sq. ft. integrated manufacturing center for innovative biologics has commenced in Chengdu, one of the largest cities in Southwest China
FDA typically conducts this inspection every two years upon product approval.